Citations

Clear

3042 citation(s) found for "Kumar, S".

ABSTRACT NUMBER: ESOC2026A1166 PERSISTENCE WITH BOTULINUM TOXIN A AND FACTORS ASSOCIATED WITH DISCONTINUATION IN PATIENTS WITH STROKE: A RETROSPECTIVE COHORT STUDY
Wainberg, Michael, Page, Simon, Zhang, Jinming , Rangarajan, Nivedita , Kumar, Sandeep, Bouchard, Jonathan, Mann, Amandeep, Beneteau, Mathieu, Schultz, Billie, Page, Simon , Mann, Amandeep, Beneteau, Mathieu , Schultz, Billie A.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i333-i334

10.1093/esj/aakag023.578 Get It

Abstract Background and aims BotulinumtoxinA (BoNT-A) is a guideline-recommended treatment for spasticity following stroke. We evaluated BoNT-A treatment persistence drivers of discontinuation and predictors of non-persistence in patients with stroke. Methods Eligible adults had received ≥1 treatment cycle with BoNT-A at the Mayo Clinic (January 2010–June 2023) and had an International Classification of Diseases (ICD9/10) code for stroke. Patients with ICD9/10 codes for migraine, cerebral palsy, cervical dystonia, or bladder dysfunction were excluded. Index date (baseline) was the date of first BoNT-A treatment; follow-up was 2 years post-index. Patients were persistent if all treatment intervals post-index were ≤the 80th percentile of all patients. Reasons for discontinuation were identified by AI natural language processing analysis of physicians’ free-text notes. Baseline characteristics associated with non-persistence were identified using step-wise logistic regression analyses. Results Overall, 407 patients were included. The 80th percentile of the BoNT-A treatment interval was 154 days; 5.7% of patients were persistent. Mean (95%CI) number of BoNT-A treatments over the 2-year follow-up was 2.43 (2.24–2.63) cycles. Comorbidity burden was high (Table 1). The most common reasons for BoNT-A discontinuation were patient- and physician-reported lack of treatment effectiveness (Table 2). Older age, Hispanic/Latino/unknown/undisclosed ethnicity, presence of comorbidities, and use of medications of interest at baseline (skeletal muscle relaxants, antidepressants, anticonvulsants, opiates, sedatives/hypnotics, NSAIDs) were significantly associated with non-persistence (Table 3). Conclusions Over 2 years, BoNT-A treatment persistence was low. Lack of treatment effectiveness was the most common reason for discontinuation. Addressing drivers of non-persistence may help improve BoNT-A treatment outcomes. Conflict of interest Funding: Ipsen. Disclosure of Conflicts of Interest: Michael Wainberg: has received consulting fees from Ipsen. Billie Schultz: has received consulting fees from Ipsen. Jinming Zhang, Simon Page, Jonathan Bouchard, Amandeep Mann, Mathieu Beneteau are employees of Ipsen. Table 1 - belongs to Conclusions Table 2 - belongs to Conclusions Table 3 - belongs to Conclusions
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
Bahlis, Nizar J. , Facon, Thierry, San-Miguel, Jesus, Usmani, Saad Z., Dimopoulos, Meletios-Athanasios A., Moreau, Philippe, Manier, Salomon , NS, Raje, Orlowski, Robert Z. , Goldschmidt, H, Hulin, Cyrille, Weisel, K, Leleu, Xavier, Plesner, Torben , Jakubowiak, Andrzej J, Cook, Gordon, Quach, H, Venner, Christopher P., Cavo, M, Ngo, Mai, Bolyard, Kasey, Carson, R, Borgsten, Fredrik, Mateos, María‐Victoria , Kumar, Shaji , Miguel, Jesús F. San , Bahlis, Nizar Jacques , San-Miguel, Jesus , Zweegman, Sonja , Perrot, Aurore , Manier, Salomon , Orlowski, Robert Z. , Goldschmidt, Hartmut , Mohty, Mohamad , Leleu, Xavier , Cook, Gordon , Quach, Hang , Mateos, María-Victoria , Kumar, Shaji K , Facon, Thierry T.F. , Usmani, Saad Z. , Dimopoulos, Meletios A , Moreau, Philippe , Chari, Ajai , Goldschmidt, Hartmut , Basu, Supratik , Hulin, Cyrille , Weisel, Katja C , Mohty, Mohamad , Leleu, Xavier , Jakubowiak, Andrzej , Cook, Gordon , Quach, Hang , Cavo, M., Carson, Robin

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: 10 | Issue: 13 | Pages: 4541-4550

10.1182/bloodadvances.2025019323 | PMID 42085642 Get It

Abstract Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care Rd (Revlimid [lenalidomide] and dexamethasone; D-Rd) or to VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP), respectively, vs Rd or VMP alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Patients with NDMM are highly susceptible to infection; therefore, gaining a greater understanding of infection incidence may help to mitigate future risk. We conducted a pooled analysis of infection incidence, timing, and management strategies from MAIA and ALCYONE. The median (range) age of the pooled population was 72 (40-93) years. Incidence was higher with D-Rd/D-VMP vs Rd/VMP for grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections; however, exposure-adjusted incidence rates were generally comparable between groups. Any-grade infections led to the discontinuation of study treatment in ∼2% of patients across treatment groups. Of the timing intervals explored, the highest incidence of grade 3/4 infection occurred within the first 6-month interval of study treatment initiation in both groups. Median time to the first onset of grade 3/4 infections (per Kaplan-Meier estimates) was 83.3 months and not estimable in the D-Rd/D-VMP and Rd/VMP groups, respectively. Although the rates of D-Rd/D-VMP treatment discontinuation due to infection remained low in MAIA and ALCYONE, clinicians should remain vigilant about infections throughout treatment and follow local guidelines and International Myeloma Working Group recommendations to minimize the risk of infection. These trials were registered at www.ClinicalTrials.gov as NCT02252172 (MAIA) and NCT02195479 (ALCYONE).
Development and validation of a lesion-supervised deep learning system for diabetic retinopathy grading according to UK national screening criteria
Chowdhury, Pradipta Narayan , Akter, Yasmin , Chowdhury, Purnashree , Kaur, Anureet, Uddin, Minhaz, Chowdhury, Anindita, Chowdhury, Prakash Kumar , Muqit, Mahi

Mayo Clinic

No container title available | April 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.27.26351799 Get It

Abstract Background Diabetic retinopathy (DR) is the leading cause of preventable blindness among working-age adults worldwide, yet screening coverage remains inadequate, particularly in low-and middle-income countries. Automated deep learning systems offer potential to address the global shortage of expert graders, but most existing models lack lesion-level interpretability and are not aligned with established clinical referral frameworks. We developed and validated DRAGS (Diabetic Retinopathy Automated Grading System), a hybrid deep learning model that grades DR according to the UK Diabetic Eye Screening Programme (DESP) classification and provides lesion-level explainability. Methods We trained and validated a DenseNet-201-based convolutional neural network on 20,281 anonymised fundus images from two tertiary eye care institutions in Bangladesh. Images were graded by fellowship-trained retinal specialists using the UK DESP framework, resulting in 10 clinically interpretable classes that combine retinopathy grade (R0–R3) and maculopathy status (M0/M1). A companion dataset of 2,936 pixel-level lesion masks spanning nine pathological categories was used to train a parallel multi-label lesion-detection head. The dataset was partitioned 70:15:15 (patient-stratified). Performance was evaluated using macro-averaged AUROC (DeLong estimator), sensitivity, specificity, F1 score, quadratically weighted Cohen’s κ, and expected calibration error (ECE), with 95% CIs from 2000 bootstrap resamples. Grad-CAM spatial alignment with ground-truth lesion masks was assessed using Dice and IoU. This study follows the TRIPOD+AI reporting guidelines. Findings On the held-out test set (Component I: n = 3,044; Component II: n ≈ 440), DRAGS achieved class-wise precision, recall, and F1 scores ranging from 0·88 to 0·99 across all ten UK DESP grades, with advanced proliferative stages (R3–M0, R3–M1) consistently exceeding 0·95. Overall accuracy was approximately 91·1% and quadratically weighted Cohen’s κ was approximately 0·90. For referable versus non-referable DR, sensitivity was 90·7% and specificity was 91·9%. The companion lesion-detection head achieved macro-averaged sensitivity of 93·9%, specificity of 99·5%, and AUC of 0·997 across nine lesion classes; seven of nine classes achieved AUC = 1·00. Grad-CAM activations showed progressive spatial shift from diffuse (normal) to lesion-dense peripheral patterns (proliferative DR), with maximal agreement for microaneurysms and exudates. Mean inference time was 110–160 ms per image. Interpretation DRAGS demonstrates high diagnostic accuracy for nine-class UK DESP-aligned DR grading, with clinically interpretable lesion-level explainability on a large real-world LMIC dataset. External validation and prospective clinical evaluation are warranted before deployment. Funding The present study received no funding.
Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort
Silvey, Scott , Choudhury, Ashok , Kamath, Patrick S. , Wong, Florence , Hayes, P C, Seto, Wai‐Kay , Singhal, Garima, Jothimani, Dinesh , Asrani, Sumeet, Gadano, Adrián , Dinçer, Dinc , Adebayo, Daneille, Doyle, Adam, Debzi, Nabil , Shaw, Jawaid , Barutçu, Sezgin , Lah, Ponan Claude Regis, Duarte‐Rojo, Andrés , Turan, Dilara , Wang, Lei, Velazquez, René Malé, Aghayaeva, Sevda, Córdova-Gallardo, J, Xu, Bin, Gao, Haibing , Elangovan, Harendran, Fung, James, Rajorya, Neil, Wang, X I A O Y U, Katchman, Helena , Jiang, Yongfang, Thanapirom, Kessarin , Eapen, CE, Dhiman, Radha K. , Lu, Mingqin, Su, Minghua , Hueso, Sarai Gonzalez, Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping, MacQuillan, Gerry, Pereira, Gustavo, Reddy, K. Rajender , Topazian, Mark, Torre, A Ullate De La, Silva, Mario, Bush, Brian J., Bajaj, Jasmohan S. , Chaudhary, Ashok , Xie, Qing , Wong, Florence , Arora, Umang , Gadano, Adrian , Dincer, Dinc , Velarde-Ruiz Velasco, José Antonio , Kulkarni, Anand V , Shaw, Jawaid , Desalgn, Hailemicheal , Bettinger, Dominik , Regis Lah, Ponan Claude , Duarte-Rojo, Andres , Turan, Dilara , Zheng, Xin , Demirtas, Coskun , Liu, Chenghai , Cordova-Gallardo, Jacqueline , Nagral, Aabha , Gao, Haibing , Katchmann, Helena , Praharaj, Dibyalochan , Mahadeva, Sanjiv , Eapen, C E , Dhiman, Radha K , Lu, Mingqin , Arrese, Marco , Su, Minghua , Hueso, Sarai Gonzalez , Aberra, Hanna , Fisseha, Henok , Tan, Hiang Keat , Zhao, Caiyan , Zhang, Ningping , Taneja, Sunil , Sonavane, Amey , Saraya, Anoop , Gofton, Cameron , Pereira, Gustavo , Rajender Reddy, K , Sarin, Shiv Kumar , Cao, Zhujun , Topazian, Mark D , Idilman, Ramazan , Torre, Aldo , George, Jacob , BUSH, BRIAN J. , Bajaj, Jasmohan S , Seto, Wai-Kay , Singhal, Garima, Asrani, Sumeet K. , Farias, Alberto Queiróz , Velasco, J.A. Velarde-Ruiz , Kulkarni, Anand V. , Desalegn, Hailemichael , Karasu, Zeki A. , Fung, James , Rajoriya, Neil , Zheng, Katina , Arrese, Marco , Zhu, Chuanwu , Taneja, Sunil , Aravinthan, Aloysious Dominic , MacQuillan, Gerry C., Idılman, Ramazan , George, Jacob , Alvares-da-Silva, Mario Reis

Mayo Clinic

American Journal of Gastroenterology | April 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004031 | PMID 42043180 Get It

INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE
Nativi-Nicolau, José , Fajardo, Johana, Galloway, Alyssa, Khella, Sami, Kumar, Nisith , Liedtke, Michaela , Lousada, Isabelle, Patrick, Tiffany, Moffitt, Colleen , Klein, Lori , Tamariz, Gabriela, Veeraraghavalu, Karthikeyan, Haddad-Angulo, Alexandra, Nativi-Nicolau, Jose , Lousada, Isabelle

Mayo Clinic

Clinical Medicine Insights: Cardiology | April 27, 2026 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/11795468261444669 | PMID 42077643 Get It

Objectives: Amyloidosis is a group of rare diseases that often manifest in multi-organ symptoms requiring an effective multidisciplinary team of care providers to manage. This study aimed to identify the best practices and key barriers to patient-centric care at US specialized amyloidosis centers (SACs) which have emerged as central hubs for multidisciplinary amyloidosis care. Methods: We conducted and analyzed interviews with 77 stakeholders of amyloidosis diseases, including specialist physicians from 17 SACs across the US, patients, patient advocacy group representatives, and referring physicians. Results: The most commonly mentioned best practices were patient-centric multidisciplinary care, timely intake of new high-risk patients, and responsiveness to patient questions. Expanding local physician education was noted as critical to earlier diagnosis. Fifteen out of 17 SACs are actively involved in clinical trials for amyloidosis treatments. Key barriers to care identified were patient distance to SACs, limited medical records and data sharing, and insurance hurdles. Most SACs keep track of metrics, such as patient volume, patient demographics, time to first appointment, as part of internal or in external registries to measure progress. Conclusion: These findings offer practical insights for optimizing amyloidosis care and highlight the structural and informational gaps that must be addressed to improve access and outcomes.
Monitored anaesthesia care without endotracheal intubation and general anaesthesia in pulsed field atrial fibrillation ablation
Wang, Weijia , Goel, Swecha, Estrada, Susan J, Hwang, Elliot , Obholz, Jacob, Dai, Qiying , Vidaillet, Humberto, Sharma, Param , Wang, Weijia , Kumar, Sanjay

Mayo Clinic

European Heart Journal Open | April 23, 2026 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/ehjopen/oeag070 | PMID 42125026 Get It

Abstract Aims Pulsed field ablation for atrial fibrillation offers shorter procedural times and improved safety compared with thermal ablation, but the optimal anaesthesia strategy remains uncertain. Most centres in the USA use general anaesthesia with endotracheal intubation, whereas monitored anaesthesia care without endotracheal intubation may be a safe and efficient alternative. Objectives To compare procedural efficiency and safety between monitored anaesthesia care and general anaesthesia for pulsed field ablation. Methods and results Consecutive adults who underwent pulsed field ablation for atrial fibrillation between 2024 and 2025 at Marshfield Clinic Health System were included. The anaesthesia approach was determined by operator preference. Procedural times, medication use, complications, and patient tolerance were recorded prospectively. Among 200 patients, 100 received monitored anaesthesia care without endotracheal intubation, and 100 received general anaesthesia. The mean age was 67 years, 42% were female, and the mean body mass index was 33 kilograms per square metre. Monitored anaesthesia care shortened case duration (77 vs. 95 min; P &lt; 0.001) and laboratory time (118 vs. 153 min; P = 0.002) and required fewer adjunct medications (P &lt; 0.001). Twenty-five procedures (25%) were challenging due to cough or motion but were all completed safely. Complications occurred in one monitored anaesthesia care case and six general anaesthesia cases (P = 0.054). Pulmonary vein isolation was achieved in all patients. Conclusion Monitored anaesthesia care without endotracheal intubation was safe, efficient, and resource-sparing compared with general anaesthesia for pulsed field atrial fibrillation ablation.
Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysis
Morecroft, Renée , Strelnikov, Jacob , Morecroft, Renee A , Phillipps, Jordan , Kumar, Amrat, Nassief, George, Mani, N. , Gould, Jennifer E., Johanns, Tanner M. , Ansstas, George

Mayo Clinic

Frontiers in Oncology | April 23, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1752725 | PMID 42109660 Get It

Introduction Approximately 50% of patients with uveal melanoma develop metastatic disease, most commonly involving the liver, and prognosis remains poor. Immunoembolization (IE) is an established liver-directed therapy for patients with liver-dominant metastatic uveal melanoma (mUM), though comparative data with other regional therapies remain limited. We present a single-center retrospective analysis of IE in hepatic mUM and compare outcomes with those reported in the Phase 3 FOCUS trial evaluating melphalan via percutaneous hepatic perfusion. Methods All patients with liver-dominant mUM treated with IE between 2010 and 2023 at our institution were included. Clinical records were reviewed for demographics, tumor characteristics, treatment details, and outcomes. The primary endpoint was disease control rate (DCR), defined as complete response (CR), partial response (PR), or stable disease (SD). Secondary endpoints included progression-free survival (PFS) and overall survival (OS), with subgroup analyses based on prior systemic therapy exposure. Descriptive statistics were used for analysis. Results Forty-three patients (62.8% female; median age 62 years; all Caucasian) underwent 249 IE procedures (mean 5.8 procedures per patient) over a median treatment duration of 9.1 months. Choroidal primaries accounted for 95.3% of cases, and 90.7% had liver-only metastases. The overall DCR was 27.9% (CR 4.7%, PR 20.9%, SD 2.3%), while 62.8% experienced disease progression. Median PFS was 0.85 months, and median OS was 32.7 months. One- and two-year OS rates were 69.8% and 55.8%, respectively. In subgroup analysis, patients who had received prior systemic therapy (n=12) demonstrated improved outcomes compared with treatment-naïve patients, with longer median PFS (29.9 vs. 7.2 months) and higher 2-year OS (60.0% vs. 47.0%). Compared with outcomes reported in the FOCUS trial, IE demonstrated shorter median PFS (0.85 vs. 9.0 months) and lower DCR (27.9% vs. 73.6%), but longer median OS (32.7 vs. 20.5 months). Discussion IE produced overall survival outcomes comparable to hepatic melphalan delivery despite lower radiographic response rates. Notably, patients previously treated with systemic therapy experienced improved outcomes, suggesting a potential sequencing effect. These findings support IE as a viable liver-directed therapy for liver-dominant mUM. Prospective, multicenter trials are warranted to clarify optimal sequencing strategies and enhance therapeutic outcomes.
A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
Lim, Kenneth J C , Greipp, Patricia T. , Kelemen, Katalin, Jevremovic, Dragan, Buadi, Francis K. , Dingli, David, Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam A, Hwa, Y., Warsame, Rahma , Kourelis, Taxiarchis , Abdallah, Nadine, Zanwar, Saurabh , Lin, Yi, Go, Ronald S., Ailawadhi, Sikander, Cooke, Rachel E. , Zordan, Adrian Carl, Ninkovic, Slavisa , Best, Sharene, Alatorre, Gabriela, Wiedmeier-Nutor, Julia Erin, Einsele, H, Kyle, Robert A, Gertz, MA, Kumar, Shaji , Rajkumar, S Vincent, Fonseca, Rafael, Gonsalves, Wilson I, Yadav, Udit , Rees, Matthew James , Greipp, Patricia T , Dispenzieri, Angela , Baughn, Linda, Buadi, Francis K , Muchtar, E , Leung, Nelson , Fonder, Amie , Hwa, Yi Lisa, Warsame, Rahma , Kourelis, Taxiarchis , Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Zanwar, Saurabh S , Siddiqui, Mustaqeem A , Parrondo, Ricardo D , Ailawadi, Sikander, Roy, Vivek , Cooke, Rachel , Best, Sharene H, Alatorre, Gabriela A, Kortüm, Martin , Chhabra, Saurabh , Bergsagel, P. Leif , Gertz, Morie A , Kumar, Shaji K , Fonseca, Rafael , Yadav, Udit , Lim, Kenneth J C , Steinhardt, Maximilian , Rees, Matthew J. , Dispenzieri, Angela , Jevremović, Dragan , Baughn, Linda B. , Dingli, David , Muchtar, Eli , Leung, Nelson , Hobbs, Miriam, Cook, Joselle , Binder, Moritz , Abdallah, Nadine , Go, Ronald S. , Siddiqui, Mustaqeem , Ailawadhi, Sikander , Roy, Vivek , Dun, Karen A. , Zordan, Adrian, Kortüm, K. Martin , Einsele, Hermann , Chhabra, Saurabh , Bergsagel, P. Leif , Kyle, R., Gertz, Morie A. , Rajkumar, S. Vincent , Fonseca, Rafaël , Gonsalves, Wilson I.

Mayo Clinic

Blood Advances | April 22, 2026 | Volume: 10 | Issue: 12 | Pages: 4286-4295

10.1182/bloodadvances.2025019136 | PMID 42018661 Get It

Abstract Solitary bone plasmacytoma (SBP) and SBP with minimal marrow involvement (SBPmm) are treated similarly with definitive radiation therapy (RT) followed by observation. However, differences in the natural disease course after RT between the two, are not well described. We performed a multicenter study assessing outcomes after RT in 141 patients with SBP and 102 with SBPmm diagnosed between January 2010 and December 2024. About 92% of patients with SBPmm progressed to multiple myeloma (MM) vs 76% of those with SBP (P = .01). Among patients with SBP, 21% progressed with a second solitary bone lesion vs 4% with SBPmm (P&lt; .01). Patients with longer time to progression (TTP) after initial RT could achieve durable responses with RT to a second solitary plasmacytoma in the absence of other myeloma-defining events (MDE). Multifocal lytic bone lesions were the most common MDE, occurring in 89% and 81% of patients with SBPmm and SBP, respectively. Patients with SBPmm had a median TTP of 15 months (95% confidence interval [CI], 14-21) compared to 43 months (95% CI, 34-55) for those with SBP (P&lt; .0001); 67% with SBPmm progressed within 2 years of diagnosis. Del(17p) and 1q+ (gain or amplification) were associated with shorter TTP to MM in SBPmm, with 2-year progression rates of 100% and 82%, respectively. We report significant differences in risk and modes of progression between SBP and SBPmm. Patients with SBPmm are at particularly high risk for early progression to MM, with most developing bone disease as the MDE. These findings support prospective studies incorporating frontline systemic therapy for SBPmm.
Endoscopic Marsupialization With Periodic Debridement for Petrous Apex Cholesteatoma
Hardy, Emily , Cirelli, Michael A. , Kumar, Neha, Lal, Devyani , Kumar, Nitish , Hardy, Emily G , Kumar, Nitish , Lal, Devyani , Patel, Naresh P.

Mayo Clinic

The Laryngoscope | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70574 | PMID 42011898 Get It

Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy
Mix, Madison R. , Sievers, Cassie M, Kannan, Shravan Kumar , Pewe, Lecia L. , He, Rui , Fain, Cori E. , Heidarian, Mohammad , Arumugam, Sahaana , Beltz, Terry G., Jin, Fang, Johnson, Aaron J., Hassert, Mariah , Huang, Sunny C. , Hancox, Lisa S. , Jin, Fang, Johnson, Aaron J. , Carter, Calvin S. , Butler, Noah S. , Salem, Aliasger K. , Badovinac, Vladimir P , Harty, John T.

Mayo Clinic

Journal of Clinical Investigation | April 14, 2026 | Volume: 136 | Issue: 8 | Pages: No page available

10.1172/jci197812 | PMID 41983390 Get It

Primary and metastatic brain tumors exhibit resistance to immunotherapies that demonstrate efficacy in peripheral cancer settings. While many immunotherapies aim to enhance CD8 + T cell infiltration and functionality in established tumors, identification of neoantigens support emerging immunopreventative tactics against brain cancer. Functionally potent tissue-resident memory CD8 + T cells (T RM ) can be generated in the brain following peripheral infection or vaccination. However, the ability of brain T RM to prevent intracranial malignancy remains unknown. Here, mice were seeded with tumor-specific or bystander brain T RM via peripheral infection prior to depletion of circulating memory T cells (T CIRCM ) and subsequent brain tumor challenge. Tumor-specific brain T RM durably protected mice against intracranial malignancy even in the absence T CIRCM . These brain T RM persisted in tumor-surviving mice and protected against a second antigen-matched challenge. Importantly, a translationally-relevant mRNA-lipid nanoparticle (LNP) vaccine phenocopied peripheral infection-induced outcomes, generating functional brain T RM that controlled tumor growth. Altogether, this work points to the utility of brain T RM in cancer immunoprevention, supporting the development of antitumor mRNA-LNP vaccines to bolster brain immunity.